Publicacions en què col·labora amb Eva Bandres Elizalde (9)

2020

  1. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

2011

  1. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas

    PLoS ONE, Vol. 6, Núm. 10

2010

  1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

  2. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

    Blood, Vol. 115, Núm. 3, pp. 615-625

2009

  1. Epigenetic regulation of MicroRNAs in acute lymphoblastic leukemia

    Journal of Clinical Oncology, Vol. 27, Núm. 8, pp. 1316-1322

  2. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

2008

  1. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth

    Molecular Cancer Research, Vol. 6, Núm. 12, pp. 1830-1840

2007

  1. Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812)

    Leukemia

  2. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

    Leukemia